drugset
Drugs / CST-107
last change Mar 2025 re-read 3 minutes ago

CST-107

Developed for
cognitive impairment with or without cerebellar ataxia · dementia · parkinsonian disorder
Investigated by
CuraSen Therapeutics, Inc.

Trials 2

today NCT04935762 · Ph 2 NCT05104463 · Ph 2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT04935762 Jun → Dec 2024 parkinsonian disorder CuraSen Therapeutics, Inc. Withdrawn No outcome recorded Stop: Business
Phase 2 NCT05104463 Apr 2022 → Dec 2023 cognitive impairment with or without cerebellar ataxia, dementia CuraSen Therapeutics, Inc. Completed No outcome recorded
Comparator or background therapy1 trial
Phase 1 NCT05033912 Background Oct 2021 → Mar 2022 Parkinson disease, cognitive disorder CuraSen Therapeutics, Inc. Withdrawn No outcome recorded Stop: Business

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2024-03-07 CuraSen Therapeutics, Inc. Results CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference curasen.com ↗
2023-03-30 CuraSen Therapeutics, Inc. Results CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference curasen.com ↗
2022-12-19 CuraSen Therapeutics, Inc. Results CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment curasen.com ↗
CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced today positive top-line safety, tolerability and proof of concept data, with early efficacy benefit, in a Phase 2 clinical trial with CST-103 in patients with Parkinson’s disease (PD) or mild cognitive impairment (MCI).
2021-11-09 CuraSen Therapeutics, Inc. Results CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease curasen.com ↗
The study also demonstrated that the common peripheral side effects of systemic administration of beta-2 agonists, such as increased heart rate, can be well managed by co-administering low doses of CST-107, a beta blocker, with CST-103.

All press releases naming this drug 5 releases

DateIssuerRelease

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as CST-107 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05104463 ↗
2

NCT05033912 ↗

NCT04935762 ↗